Combining new therapies for high-risk chronic lymphocytic leukemia
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
This study is testing a new combination of three medicines to see if it can help people with high-risk chronic lymphocytic leukemia (CLL) who haven't started treatment yet, with the goal of making the cancer undetectable and improving their overall health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10890036 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for patients with high-risk chronic lymphocytic leukemia (CLL) who have not yet received treatment. It focuses on a combination of three agents: a BTK inhibitor, a BCL-2 inhibitor, and an anti-CD20 antibody, aiming to improve patient outcomes by achieving undetectable minimal residual disease. The study will evaluate the effectiveness and safety of this combination therapy through a clinical trial, while also exploring factors that may predict how well patients respond to the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with previously untreated high-risk chronic lymphocytic leukemia, particularly those with TP53 aberrations.
Not a fit: Patients with chronic lymphocytic leukemia who have already received treatment or do not have high-risk features may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved survival rates for patients with high-risk CLL.
How similar studies have performed: Previous research has shown promising results with similar combination therapies in treating CLL, indicating potential for success in this novel approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Davids, Matthew S — Dana-Farber Cancer Inst
- Study coordinator: Davids, Matthew S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.